Medical Developments International (ASX:MVP) - Share price, News & Analysis

MVP fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

MVP Stock Overview

Medical Developments International Limited manufactures and distributes pharmaceutical and veterinary products, and medical devices.

Rewards

Revenue is forecast to grow 43.05% per year

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years

Medical Developments International Competitors

Cronos Australia

ASX:CAU

AU$137.7m

Recce Pharmaceuticals

ASX:RCE

AU$135.3m

Probiotec

ASX:PBP

AU$186.2m

Ecofibre

ASX:EOF

AU$124.1m

Price History & Performance

Summary of all time highs, changes and price drops for Medical Developments International
Historical stock prices
Current Share Price	AU$2.66
52 Week High	AU$5.45
52 Week Low	AU$2.80
Beta	1.21
1 Month Change	-25.49%
3 Month Change	-26.32%
1 Year Change	-46.69%
3 Year Change	-49.81%
5 Year Change	-43.52%
Change since IPO	454.17%

Recent News & Updates

Mar 04

Some Analysts Just Cut Their Medical Developments International Limited (ASX:MVP) Estimates

The latest analyst coverage could presage a bad day for Medical Developments International Limited ( ASX:MVP ), with...

Shareholder Returns

	MVP	AU Pharmaceuticals	AU Market
7D	-6.7%	-3.7%	-1.2%
1Y	-46.7%	-17.9%	-0.009%

Return vs Industry: MVP underperformed the Australian Pharmaceuticals industry which returned -17.9% over the past year.

Return vs Market: MVP underperformed the Australian Market which returned -0% over the past year.

Price Volatility

Is MVP's price volatile compared to industry and market?
MVP volatility
MVP Average Weekly Movement	11.5%
Pharmaceuticals Industry Average Movement	10.4%
Market Average Movement	9.3%
10% most volatile stocks in AU Market	16.3%
10% least volatile stocks in AU Market	4.2%

Stable Share Price: MVP is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: MVP's weekly volatility (12%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2003	68	Brent MacGregor	https://medicaldev.com

Medical Developments International Limited manufactures and distributes pharmaceutical and veterinary products, and medical devices. The company operates through three segments: Pharmaceuticals, Medical Devices, and Veterinary Products. It offers asthma and COPD pressurized metered dose inhalers, as well as masks and peak flow meters for asthma management for use in home or in hospitals; Penthrox, a prescription only medicine for pain in trauma; and medical devices, such as CPR face shield key rings, CPR masks, finger pulse oximeters, flow meter regulators, MDI tourniquets, manually triggered ventilators, OXI port carry and hand bags, resuscitation kits, oxygen therapy masks, and resuscitators.

Medical Developments International Fundamentals Summary

How do Medical Developments International's earnings and revenue compare to its market cap?
MVP fundamental statistics
Market Cap	AU$199.65m
Earnings (TTM)	-AU$18.81m
Revenue (TTM)	AU$22.30m

8.5x

P/S Ratio

-10.1x

P/E Ratio

Is MVP overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
MVP income statement (TTM)
Revenue	AU$22.30m
Cost of Revenue	AU$7.37m
Gross Profit	AU$14.93m
Other Expenses	AU$33.73m
Earnings	-AU$18.81m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	-0.26
Gross Margin	66.95%
Net Profit Margin	-84.35%
Debt/Equity Ratio	0%

How did MVP perform over the long term?

See historical performance and comparison

New valuation analysis is now available for all ASX stocks. This is in beta.

Future Growth

How is Medical Developments International forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

53.2%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MVP is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MVP is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MVP is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MVP's revenue (43.1% per year) is forecast to grow faster than the Australian market (4.8% per year).

High Growth Revenue: MVP's revenue (43.1% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: MVP is forecast to be unprofitable in 3 years.

Past Performance

How has Medical Developments International performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-85.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: MVP is currently unprofitable.

Growing Profit Margin: MVP is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: MVP is unprofitable, and losses have increased over the past 5 years at a rate of 85.8% per year.

Accelerating Growth: Unable to compare MVP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MVP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10.9%).

Return on Equity

High ROE: MVP has a negative Return on Equity (-30.33%), as it is currently unprofitable.

Financial Health

How is Medical Developments International's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: MVP's short term assets (A$40.5M) exceed its short term liabilities (A$9.1M).

Long Term Liabilities: MVP's short term assets (A$40.5M) exceed its long term liabilities (A$24.9M).

Debt to Equity History and Analysis

Debt Level: MVP is debt free.

Reducing Debt: MVP has no debt compared to 5 years ago when its debt to equity ratio was 2.2%.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MVP has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: MVP has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 37.7% each year.

Dividend

What is Medical Developments International current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate MVP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MVP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MVP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MVP's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: MVP is not paying a notable dividend for the Australian market.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MVP has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure

CEO

Brent MacGregor (57 yo)

1.5yrs

Tenure

AU$1,325,143

Compensation

Mr. Brent MacGregor serves as Director at Dynavax Technologies Corporation since July 2020. He has been the Chief Executive Officer of Medical Developments International Limited since November 01, 2020. Mr...

CEO Compensation Analysis

Compensation vs Market: Brent's total compensation ($USD936.76K) is above average for companies of similar size in the Australian market ($USD291.26K).

Compensation vs Earnings: Insufficient data to compare Brent's compensation with company performance.

Leadership Team

Experienced Management: MVP's management team is considered experienced (2.8 years average tenure).

Board Members

Experienced Board: MVP's board of directors are considered experienced (4.7 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/25 00:00
End of Day Share Price	2022/05/25 00:00
Earnings	2021/12/31
Annual Earnings	2021/06/30